Abstract
To test whether simply increasing plasma potassium with amiloride would exert any of the same beneficial effects on "surrogate outcome measures" that are seen with spironolactone. The latter has been shown to improve mortality in chronic heart failure, possibly as a result of improvements in endothelial dysfunction, vascular angiotensin converting enzyme (ACE), autonomic function, myocardial fibrosis, ventricular arrhythmias, and QT interval indices.
Original language | English |
---|---|
Pages (from-to) | 475-80 |
Number of pages | 6 |
Journal | Heart (British Cardiac Society) |
Volume | 88 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2002 |